THE Health Department's public consultation process on the Post-Market Review of Pulmonary Arterial Hypertension (PAH) medicines has now closed.
An additional medicine, riociguat, has been added to the review, with affected contributors invited to update their submission if required.
For more info see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 17
